STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states

Sandoz has reached a $478.5 million settlement to resolve price-fixing allegations brought by multiple states and resellers of medicines. The pharmaceutical company admitted no wrongdoing in the case. The settlement includes $400 million over seven years starting in 2027 to address remaining claims by U.S. states in three pending cases, along with an additional $50 million to states that had already settled.

Furthermore, $28.5 million will be allocated to resolve any remaining class-action litigation filed by indirect resellers. This latest agreement is part of an ongoing dispute between states and major generic drug manufacturers accused of manipulating drug prices for their benefit. Notably, Glenmark Pharmaceuticals, Lannett, Bausch, Apotex, and Heritage Pharmaceuticals previously settled for around $98 million.